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Background: The US Food and Drug Administration has issued warnings about a potential link 
between leukotriene receptor-modifying agents (LTMA) and suicide. These warnings are based 
on case reports and there is controversy about the association. While spontaneous reporting of 
suicide-related events attributed to LTMA has risen dramatically, these data may be biased by 
the warnings. The objective of this study was to explore the relationship between LTMA and 
suicide deaths using event data preceding the Food and Drug Administration warnings.
Methods: We conducted a mixed-effects Poisson regression analysis of the association between 
LTMA prescriptions dispensed and suicide deaths at the county level. Counts of suicide deaths 
in each US county, stratified by race, age group, gender, and year were obtained from the 
National Center for Health Statistics for the period January 1, 1999 to December 31, 2006. 
Counts of LTMA prescriptions dispensed in each US county were obtained from IMS Health 
Incorporated. The model estimated the overall suicide rate conditional on LTMA use, adjusted 
for age, gender, race, year, and antidepressant utilization. We also assessed the intracounty and 
intercounty associations.
Results: There were 249,872 suicides in the US between 1999 and 2006, and the annual sui-
cide rate ranged from 11.17 to 11.92 per 100,000 population. There were 118.63, 11.68, and 
0.12   million prescriptions dispensed for montelukast, zafirlukast, and zileuton, respectively, 
between 1999 and 2006. The mean rate of LTMA prescriptions dispensed by county was 42.91 
(95% confidence interval [CI] 42.78–43.04), 4.82 (95% CI 4.81–4.84), and 0.05 (95% CI 
0.05–0.05) per 1000 for montelukast, zafirlukast, and zileuton, respectively. We found a nega-
tive within-county association between the rate of total LTMA prescriptions dispensed and the 
suicide rate by county (P = 0.0296). This association was primarily driven by montelukast.
Conclusion: Our results, while subject to certain limitations, provide preliminary evidence that 
the association between LTMA and suicide could be different (ie, reduced risk) than that which 
might be anticipated based on previous warnings. Patient-level research is needed to understand 
more clearly the association between LTMA and suicide.
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Introduction
In 2008, the US Food and Drug Administration (FDA) issued a warning about a poten-
tial link between montelukast (Singulair®, Merck & Co Inc, Whitehouse Station, NJ) 
and suicide.1 Later, the warning was expanded to all leukotriene receptor-modifying 
agents (LTMA).2,3 These warnings were based primarily on information from case 
reports. Subsequently, several retrospective evaluations of clinical trial data were con-
ducted, but these found no elevated risk of suicide or other behavior-related adverse Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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events in those treated with LTMA compared with placebo.3–6 
As a result there was, and remains, controversy about the 
proposed association.7
Following the initial FDA warning, there was a sharp 
increase in the number of suicide-related events reported to 
the FDA’s Adverse Events Reporting System where LTMA 
were considered the suspect drug.8 Over 800 such events 
were reported in 2008 and 2009, while only 33 were reported 
during the 10 years prior to the FDA warnings. The timing 
of these “spontaneous reports” in relation to FDA warnings 
makes it difficult to make conclusions about the association 
using these data.
In the case of suicides, other sources of data are avail-
able that may be used to investigate drug-event associations, 
while avoiding the limitations associated with spontaneously 
reported adverse events data. Gibbons et al used data from 
the National Center for Health Statistics, a division of the 
Centers for Disease Control of the US Department of Health 
and Human Services, to obtain the number of suicides by 
county in the US. These data were combined with prescrip-
tion rates for antidepressants to examine the association 
between antidepressants and suicides.9,10 Here we apply the 
same methodology to explore further the potential association 
between LTMA and suicide.
Methods
We conducted a mixed-effects Poisson regression analysis 
of the association between LTMA prescriptions dispensed 
and suicides at the county level (ie, county was the cluster-
ing variable). Annual counts of suicide deaths occurring in 
each county of the US were obtained from the Compressed 
Mortality File available from the National Center for Health 
Statistics for the period January 1, 1999 to December 31, 
2006 (most recent available).11 Mortality data in the Com-
pressed Mortality File are based on information from all death 
certificates filed in the 50 states and the District of Columbia, 
excluding deaths of nonresidents (eg, deaths of nonresident 
aliens, nationals residing abroad, and residents of Puerto 
Rico, the Virgin Islands, Guam, and other territories of the 
US) and fetal deaths. The suicide counts we obtained for 
each county were stratified by race (black or nonblack), age 
group (5–14, 15–24, 25–44, 45–64, and 65 years and older), 
gender, and year. The population of each county for these 
same subgroups was also obtained from the National Center 
for Health Statistics.
We obtained counts of the number of LTMA prescrip-
tions dispensed in each county of the US from the Xponent™ 
database, IMS Health Incorporated, for the same time period. 
These data were based on total dispensed   prescriptions 
from retail (chain, independent, food stores, and mass 
  merchandisers) pharmacies in the US. These data were not 
available for the demographic subgroups as were the Centers 
for Disease Control data. Further, these data do not provide 
information on whether the prescriptions were taken by 
patients, nor do they provide information on the number of 
patients taking the medications. Nevertheless, these data are 
commonly used for measuring prescription dispensations and 
are a reliable representation of total prescriptions dispensed in 
the US. Because antidepressant use has been associated with 
suicide, we also obtained counts of antidepressant prescrip-
tions dispensed by county from the IMS database to use as 
a covariate in our analysis.
To relate LTMA prescription use to suicide rate, adjust-
ing for county-specific sociodemographic characteristics, we 
used a mixed-effects Poisson regression model in a manner 
similar to that of Gibbons et al.9,10 The model estimated the 
overall suicide rate conditional on age, gender, race, year, 
and LTMA use. We also included antidepressant drug pre-
scriptions dispensed as a covariate. In one model, LTMA 
were combined into a single variable, and in another each 
LTMA (montelukast, zafirlukast, and zileuton) was included 
separately to examine individual drug effects. To account for 
differential population sizes across counties, counts of LTMA 
and antidepressant prescriptions dispensed were divided by 
the population of each county in each year. To decompose the 
overall relationship between suicides and LTMA prescrip-
tions dispensed into intracounty and intercounty components, 
we included in the models, variables representing the county 
mean drug prescriptions and a yearly deviation from the mean 
for each LTMA. In the models, age, gender, race, year, anti-
depressant prescriptions dispensed, and LTMA prescriptions 
dispensed were considered fixed effects, while the intercept 
(ie, county) was treated as a random effect.
Results
There were 249,872 suicides in the US between 1999 and 
2006 (inclusive). As shown in Table 1, the annual suicide rate 
for the entire population ranged from 11.17 per 100,000 (in 
2000) to 11.92 per 100,000 (in 2006), with an average of 11.61 
per 100,000 for the entire time period. The rate varied widely 
by age group, race, and gender, with nonblack males having 
the highest rates (20.18 per 1000) and black females the lowest 
(1.80 per 1000). We also calculated suicide rates at the county 
level. These varied widely with an average county-level 
suicide rate over the entire time period of 11.42 per 100,000 
(95% confidence interval [CI] 11.40–11.45).Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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Table 1 Observed suicide rates by age, race, and gender for each year (1999–2006). The rates shown in this table were calculated 
using the number of suicide deaths and the population by group, both of which were obtained from the national center for Health 
Statistics, for the period January 1, 1999 to December 31, 2006
Group by age Suicide rate per 100,000 population
1999 2000 2001 2002 2003 2004 2005 2006 Total
5–14 years
  Black females 0.21 0.15 0.24 0.18 0.27 0.57 0.43 0.22 0.28
  non-black females 0.26 0.34 0.32 0.34 0.26 0.44 0.31 0.34 0.32
  Black males 0.64 1.01 0.84 0.81 1.02 0.82 0.80 0.90 0.86
  non-black males 0.98 1.10 0.94 0.89 0.82 0.81 0.95 0.65 0.89
  Total 0.60 0.71 0.62 0.60 0.56 0.64 0.64 0.51 0.61
15–24 years
  Black females 1.91 2.19 1.25 1.68 1.98 2.17 1.70 1.77 1.83
  non-black females 3.26 3.12 3.18 3.15 3.22 3.82 3.84 3.48 3.39
  Black males 14.30 14.09 12.98 11.31 12.14 12.23 11.52 10.56 12.34
  non-black males 17.19 17.50 17.13 17.29 16.68 17.59 17.01 17.18 17.19
  Total 10.08 10.17 9.88 9.84 9.68 10.35 10.01 9.87 9.98
25–44 years
  Black females 2.47 2.64 2.64 2.45 2.74 2.84 2.77 1.99 2.57
  non-black females 6.02 5.86 5.95 6.38 6.14 6.51 6.28 6.55 6.21
  Black males 15.01 14.31 14.36 15.10 14.33 13.76 13.76 14.28 14.36
  non-black males 22.51 22.24 23.11 23.24 23.07 22.94 22.75 22.60 22.81
  Total 13.56 13.34 13.78 14.05 13.85 13.93 13.75 13.78 13.76
45–64 years
  Black females 1.82 2.12 2.58 2.08 2.37 2.19 2.44 1.90 2.19
  non-black females 6.56 6.70 7.14 7.30 7.55 8.30 7.80 8.52 7.52
  Black males 9.68 9.90 9.63 9.60 8.99 10.09 9.42 9.81 9.64
  non-black males 22.05 22.54 23.90 25.10 25.19 25.23 25.65 26.46 24.61
  Total 13.22 13.52 14.32 14.88 15.02 15.42 15.35 16.01 14.78
.65 years
  Black females 1.47 1.29 1.59 1.14 1.39 0.74 1.45 0.71 1.21
  non-black females 4.61 4.29 4.10 4.38 4.02 4.08 4.24 4.17 4.23
  Black males 12.48 11.56 11.47 11.64 9.12 11.26 10.18 10.22 10.96
  non-black males 33.80 32.69 33.02 33.42 31.44 30.45 31.13 30.01 31.96
  Total 15.77 15.16 15.24 15.56 14.57 14.28 14.67 14.19 14.92
All ages
  Black females 1.71 1.85 1.83 1.69 1.94 1.96 1.97 1.49 1.80
  non-black females 4.71 4.64 4.76 4.99 4.94 5.38 5.21 5.45 5.02
  Black males 10.55 10.32 10.06 9.99 9.65 9.86 9.54 9.66 9.94
  non-black males 19.55 19.52 20.14 20.58 20.27 20.32 20.46 20.54 20.18
  Total (entire population) 11.22 11.17 11.48 11.76 11.60 11.84 11.81 11.92 11.61
There were 118.63, 11.68, and 0.12 million prescrip-
tions dispensed for montelukast, zafirlukast, and zileuton, 
respectively, between 1999 and 2006. Adjusted for the 
population, the rate of prescriptions was 55.10, 5.19, and 
0.05 per 1000, as shown in Table 2. These rates varied 
by year. The mean LTMA prescription dispensing rate 
by county was 42.91 per 1000 (95% CI 42.78–43.04) for 
montelukast, 4.82 per 1000 (95% CI 4.81–4.84) for zafirlu-
kast, and 0.05 (95% CI 0.053–0.054) per 1000 population 
for zileuton.
Adjusting for county-specific sociodemographic char-
acteristics and antidepressant use, we found a negative 
within-county association between the rate of total LTMA 
prescriptions dispensed and the suicide rate. Specifically, we 
observed that within a given county a one unit increase in pre-
scriptions dispensed for LTMA (ie, one prescription per 1000 
population) was associated with a 0.03% decrease in the sui-
cide rate (maximum marginal likelihood estimate = −0.0003, 
P = 0.0296). The between-county effect was not significant. 
To determine whether the observed association was specific to 
only certain drugs in the LTMA class, we fit a model contain-
ing each of the individual drugs. Here we found a statistically 
significant negative (within-county but not between-county) 
association for montelukast (maximum marginal likelihood 
estimate = −0.0003, P = 0.0217), but not zafirlukast (maxi-
mum marginal likelihood estimate = −0.0016, P = 0.1687) or Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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Table 2 Observed rate of prescriptions dispensed for leukotriene-modifying agents by year. The rates shown were calculated using 
the number of prescriptions dispensed for each leukotriene-modifying agent, which was obtained from the Xponent™ database, iMS 
Health incorporated (all rights reserved), January 1, 1999 to December 31, 2006; and along with the population data which were 
obtained from the national center for Health Statistics, for the same period
Drug Prescriptions dispensed per 1000 population
1999 2000 2001 2002 2003 2004 2005 2006 Total
Montelukast 12.77 29.58 39.77 47.09 61.45 72.27 79.20 89.46 55.10
Zafirlukast 7.93 8.43 6.90 5.37 4.18 3.28 2.59 2.17 5.19
Zileuton 0.14 0.11 0.08 0.06 0.05 0.01 0.01 0.09 0.05
class overall 20.83 38.12 46.75 52.52 65.68 75.57 81.81 91.72 60.34
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Figure  1  relationship  between  county-level  montelukast  prescribing  rate  per 
1000 population and county-level suicide rate per 100,000 population, 1999–2006. 
The horizontal axis is montelukast prescriptions dispensed per 1000 population in 
quartiles, while the corresponding mean suicide rate per 100,000 is shown on the 
vertical axis. For example, the mean suicide rate for counties in the lowest quartile of 
montelukast prescriptions dispensed per 1000 population was 12.97, while the mean 
rate was 10.02 for counties in the highest quartile. The number of suicide deaths 
by county and the population by county were obtained from the national center 
For Health Statistics, for the period January 1, 1999 to December 31, 2006, and 
was used to calculate the suicide rate. The number of prescriptions for montelukast 
by county was obtained from the Xponent™ database, iMS Health incorporated 
(all rights reserved), for the same time period, and along with the population data 
was used to calculate the rate of montelukast prescriptions dispensed per 1000 
population.
zileuton (maximum marginal likelihood estimate = −0.0022, 
P = 0.8890), although the direction of the effect was consis-
tent across all three drugs. The estimated rate multiplier for 
the montelukast within-county effect was 0.9997 (95% CI 
0.9994–0.9999), which means that for every unit increase 
in montelukast prescriptions (ie, one prescription per 1000 
population) there is a corresponding decrease in the rate of 
suicides by 0.03%.
Figure 1 shows graphically the relationship between 
county-level rate of montelukast prescriptions dispensed 
and the county-level suicide rate. The horizontal axis is 
montelukast prescriptions dispensed per 1000 population 
in quartiles, while the corresponding mean suicide rate per 
100,000 is shown on the vertical axis. For example, the mean 
suicide rate for counties in the lowest quartile of montelukast 
prescriptions dispensed per 1000 population was 12.97, while 
the rate was 10.02 in the highest quartile. Figure 1 shows 
visually the negative association described above.
Discussion
Our analysis was performed by combining county-level 
data on suicide deaths with data on prescriptions dispensed 
for LTMA, and as such was intended to be exploratory. Our 
main observation, ie, that as the number of prescriptions 
dispensed for montelukast increases within a given county 
the rate of suicides decreases, is contrary to that which one 
might anticipate, given the FDA warnings about LTMA and 
the subsequent increase in spontaneous reports of suicides 
linked to montelukast. Such a finding does not necessarily 
negate the importance of the FDA warning, which is intended 
to alert prescribers and the public about the possibility that 
the development of suicidal thoughts or actions may occur 
in some patients. After all, it is possible that in some patients 
the drug(s) increase risk while in others risk is mitigated. 
Nevertheless, because such warnings can result in important 
drugs being withheld from patients who might otherwise 
benefit from them, it is important to conduct research that 
might better inform clinical decision-making.
It is not clear how montelukast may reduce suicides, if 
indeed that is the case. However, both asthma and allergic 
rhinitis, ie, the two FDA-approved indications for montelu-
kast, are associated with increased risk for suicide and related 
behavior. Asthma has also been associated with a 2–3 times 
higher risk for suicidal ideation,12–14 and more than four 
times higher likelihood of suicide attempts.14,15 Some data 
suggest that asthma symptoms, including “breathlessness”, 
pain, and functional limitations, may contribute to suicide, 
possibly via depression.16 Similarly, higher rates of suicide 
have been observed in those with allergic rhinitis and other 
allergic disorders, and seasonal variation in suicide rates has 
been linked to corresponding peaks in disease.17–19 It is pro-
posed that seasonal increases in pollen may result in onset of 
symptoms of the disease which then lead to worsening mood 
or depression, ie, the most common risk factor for suicide.20 Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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Allergic conditions have also been associated with anxiety, 
depression, hostility/aggression, and sleep disturbance, all of 
which in turn may be associated with suicide.21–25
Better control of asthma or allergic rhinitis results in 
reduced symptoms of disease. Therefore, a reasonable expla-
nation of our finding could be that LTMA, because they are 
effective in reducing symptoms, reduce the risk of suicide. 
Still, our results should be considered in the context of the 
limitations present in our data and in our study design. This 
was an ecologic study that, like all such studies, had certain 
limitations that could have confounded our results. These are 
described in the following paragraphs.
We obtained data on suicides from the National Center 
for Health Statistics. These data are derived from death 
certificates. Biases associated with miscoding on death 
certificates have been previously discussed.26 However, the 
sensitivity and specificity of coding of deaths due to suicide 
has been shown to be very high (.90%).27 Nevertheless, 
some uncontrolled variability may exist due to differences 
at the county level in qualifications of coroners or medical 
examiners, frequency and extent of case investigations, and 
definitions of suicide, which may lead to differential suicide 
rates. The population estimates for subgroups (by age, gender, 
race) within counties were also obtained from the National 
Center for Health Statistics Compressed Mortality File. These 
estimates are projected based on previous census figures 
and may not be accurate in counties where demographics 
are changing rapidly.
In our analysis we also used data on retail prescriptions for 
LTMA dispensed in the US. While the retail distribution chan-
nel from which these data come likely captured a majority of 
the use of these drugs, some utilization may occur in hospitals, 
mail order pharmacies, or other settings not included in these 
data. Further, while the data we used are projected to account 
for 100% of the market, the accuracy of such projections at 
the county level is unknown. It is also true that prescriptions 
dispensed are not necessarily the same as exposure because of 
the inability to measure patient   adherence. However, there is 
substantial literature validating the use of prescription claims 
as a measure of drug exposure.28,29 Last, while there was 
substantial use of montelukast across the US in our data, the 
lower overall rate of prescriptions for zafirlukast and zileuton 
may have limited our power to detect an association with these 
drugs if one had existed.
Finally, while we controlled for a number of factors that 
could confound our results, the data sources we used did 
not contain many variables that could help us to adjust for 
confounding in the relationship between LTMA use and sui-
cide. For example, we did not control for county-level preva-
lence of asthma or allergic rhinitis, or for other diseases (ie, 
mental disorders), behaviors (ie, drug abuse or alcoholism), 
or socioeconomic factors that have been shown to increase 
the risk of suicide. Nor did we control for homicide or fatal 
accident rates, availability of mental health services, or use 
of prescription drugs other than antidepressants that may be 
associated with suicide.
Because our study was ecologic in nature, we are not able 
to draw any causal inferences from these data. Nevertheless, 
these results raise questions about the potential LTMA-
suicide relationship and provide preliminary evidence, at 
least for montelukast, that for some patients the association 
may actually be in the opposite direction (ie, reduced risk) 
of that anticipated from the warnings. Clearly, additional 
patient-level research is needed to establish the presence 
of an association between LTMA and suicide more defini-
tively, and to understand better if there might be subgroups 
of patients that differ with respect to level of risk or even 
direction of effect.
Disclosure
No funding was received for the conduct of this study. Dr Lee 
has served as a consultant for Merck and has been an inves-
tigator on a grant funded in part by Astra Zeneca – both of 
which are manufacturers of drugs included in this study. The 
other authors report no conflicts of interest in this work. All 
persons who made substantial contributions to the work are 
included as authors. The statements, findings, conclusions, 
views, and opinions contained and expressed in this article are 
based in part on data obtained under license from the following 
IMS Health Incorporated information service(s): Xponent™, 
January 1999 – December 2009, IMS Health Incorporated. 
All Rights Reserved. Such statements, findings, conclusions, 
views, and opinions are not necessarily those of IMS Health 
Incorporated or any of its affiliated or subsidiary entities. 
Similarly, data from the National Center for Health Statistics 
as used in this analysis. All analysis, interpretations, and 
conclusions reached from these data are those of the authors 
and not the National Center for Health Statistics.
References
1.  US Food and Drug Administration. Early communication about an 
ongoing safety review of montelukast (Singulair), 2009. Postmarket 
drug safety information for patients and providers. Available at: http://
www.fda.gov/drugs/drugsafety/  postmarketdrugsafetyinformationfor 
patientsandproviders/drugsafetyinformationforhealthcareprofessionals/
ucm070618.htm. Accessed June 24, 2011.Drug, Healthcare and Patient Safety
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/drug-healthcare-and-patient-safety-journal
Drug, Healthcare and Patient Safety is an international, peer-reviewed 
open-access journal exploring patient safety issues in the healthcare 
continuum from diagnostic and screening interventions through to treat-
ment, drug therapy and surgery. The journal is characterized by the rapid 
reporting of reviews, original research, clinical, epidemiological and 
post-marketing surveillance studies, risk management, health literacy 
and educational programs across all areas of healthcare delivery. The 
manuscript management system is completely online and includes a very 
quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
52
Schumock et al
  2.  US Food and Drug Administration. Updated information on leukotriene 
inhibitors: Montelukast (marketed as Singulair), zafirlukast (marketed as 
Accolate), and zileuton (marketed as Zyflo and Zyflo CR), 2009. Post-
market drug safety information for patients and providers. Available at: 
http://www.fda.gov/drugs/drugsafety/  postmarketdrugsafetyinformation 
forpatientsandproviders/drugsafetyinformationforhealthcareprofession 
als/ucm165489.htm. Accessed June 24, 2011.
  3.  US Food and Drug Administration. Follow-up to the March 27, 2008 com-
munication about the ongoing safety review of montelukast   (Singulair), 
2009. Postmarket drug safety information for patients and providers. 
Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrug 
safetyinformationforpatientsandproviders/  drugsafetyinformationforhea
lthcareprofessionals/ucm079523.htm. Accessed June 24, 2011.
  4.  Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of mon-
telukast in placebo-controlled pediatric studies and their open-label 
extensions. Pediatr Pulmonol. 2009;44(6):568–579.
  5.  Philip G, Hustad C, Noonan G, et al. Reports of suicidality in clinical 
trials of montelukast. J Allergy Clin Immunol. 2009;124(4):691–696.
  6.  Philip G, Hustad CM, Malice MP, et al. Analysis of behavior-related 
adverse experiences in clinical trials of montelukast. J Allergy Clin 
Immunol. 2009;124(4):699–706.
  7.  [No authors listed]. Joint statement on FDA investigation of Singulair 
from the ACAAI and AAAAI. Eur Ann Allergy Clin Immunol. 2008; 
40(2):64.
  8.  Schumock GT, Lee TA, Joo MJ, Valuck RJ, Stayner LT, Gibbons RD. 
Association between leukotriene-modifying agents and suicide: What 
is the evidence? Drug Saf. 2011;34(7):533–544.
  9.  Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between 
antidepressant medication use and rate of suicide. Arch Gen Psychiatry. 
2005;62(2):165–172.
  10.  Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between 
antidepressant prescription rates and rate of early adolescent suicide. 
Am J Psychiatry. 2006;163(11):1898–1904.
  11.  National Center for Health Statistics. Compressed Mortality File,1999–
2006. Hyattsville, MD: National Center for Health Statistics; 2009.
  12.  Goodwin RD, Olfson M, Shea S, et al. Asthma and mental disorders in 
primary care. Gen Hosp Psychiatry. 2003;25(6):479–483.
  13.  Goodwin RD, Marusic A. Asthma and suicidal ideation among youth 
in the community. Crisis. 2004;25(3):99–102.
  14.  Goodwin RD, Eaton WW. Asthma, suicidal ideation, and suicide 
attempts: Findings from the Baltimore epidemiologic catchment area 
follow-up. Am J Public Health. 2005;95(4):717–722.
  15.  Druss B, Pincus H. Suicidal ideation and suicide attempts in general 
medical illnesses. Arch Intern Med. 2000;160(10):1522–1526.
  16.  Harwood DM, Hawton K, Hope T, Harriss L, Jacoby R. Life problems 
and physical illness as risk factors for suicide in older people: A descrip-
tive and case-control study. Psychol Med. 2006;36(9):1265–1274.
  17.  Timonen M, Viilo K, Hakko H, et al. Is seasonality of suicides stron-
ger in victims with hospital-treated atopic disorders? Psychiatry Res. 
2004;126(2):167–175.
  18.  Massing W, Angermeyer MC. The monthly and weekly distribution of 
suicide. Soc Sci Med. 1985;21(4):433–441.
  19.  Chew KS, McCleary R. The spring peak in suicides: A cross-national 
analysis. Soc Sci Med. 1995;40(2):223–230.
  20.  Postolache TT, Stiller JW, Herrell R, et al. Tree pollen peaks are asso-
ciated with increased nonviolent suicide in women. Mol Psychiatry. 
2005;10(3):232–235.
  21.  Postolache TT, Komarow H, Tonelli LH. Allergy: A risk factor for 
suicide? Curr Treat Options Neurol. 2008;10(5):363–376.
  22.  Goodwin RD, Castro M, Kovacs M. Major depression and allergy: 
Does neuroticism explain the relationship? Psychosom Med. 
2006;68(1):94–98.
  23.  Timonen M, Jokelainen J, Herva A, Zitting P, Meyer-Rochow VB, 
Rasanen P. Presence of atopy in first-degree relatives as a predictor of 
a female proband’s depression: Results from the northern Finland 1966 
birth cohort. J Allergy Clin Immunol. 2003;111(6):1249–1254.
  24.  Timonen M, Jokelainen J, Hakko H, et al. Atopy and depression: Results 
from the Northern Finland 1966 birth cohort study. Mol Psychiatry. 
2003;8(8):738–744.
  25.  Timonen M, Jokelainen J, Silvennoinen-Kassinen S, et al. Association 
between skin test diagnosed atopy and professionally diagnosed depres-
sion: A Northern Finland 1966 birth cohort study. Biol Psychiatry. 2002; 
52(4):349–355.
  26.  Rosenberg H. Improving cause-of-death statistics. Am J Public Health. 
1989;79(5):563–564.
 27.  Moyer LA, Boyle CA, Pollock DA. Validity of death   certificates for 
  injury-related causes of death. Am J Epidemiol. 1989;130(5):1024–1032.
  28.  Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation 
of medication adherence and persistence using automated databases. 
Pharmacoepidemiol Drug Saf. 2006;15(8):565–574.
  29.  Lau HS, De Boer A, Beuning KS, Porsius A. Validation of phar-
macy records in drug exposure assessment. J Clin Epidemiol. 1997; 
50(5):619–625.